Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes
The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)
Article Information
vol. 29 no. 7 1478-1485
PubMed
Published By
Print ISSN
Online ISSN
History
- April 17, 2006
- December 8, 2005
- Published in print June 26, 2006.
Copyright & Usage
DIABETES CARE
Author Information
- Robert H. Knopp, MD1,
- Michael d’Emden, MD2,
- Johan G. Smilde, MD, PHD3,
- Stuart J. Pocock, PHD4 and
- on behalf of the ASPEN Study Group*
- 1Department of Medicine and the Northwest Lipid Research Clinic, University of Washington School of Medicine, Seattle, Washington
- 2Department of Medicine, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia
- 3Department of Internal Medicine, Refaja-Hospital, Stadskanaal, the Netherlands
- 4Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, U.K.
- Address correspondence and reprint requests to Chief Robert H. Knopp, Harborview Medical Center, 325 Ninth Ave., #359720, Seattle, WA 98104-2499. E-mail: rhknopp{at}u.washington.edu